Results 201 to 210 of about 2,551,103 (363)

Efficacy and Safety of ABBV‐154 for the Treatment of Active Rheumatoid Arthritis: A Phase 2b, Randomized, Placebo‐Controlled Trial

open access: yesArthritis &Rheumatology, Accepted Article.
Objective Despite availability of biologics and targeted synthetic disease‐modifying antirheumatic drugs (b/tsDMARDs) to treat rheumatoid arthritis (RA), many patients do not experience optimized disease control. Glucocorticoids are effective but have safety risks.
Frank Buttgereit   +13 more
wiley   +1 more source

AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury

open access: yes, 2022
Hepatology, EarlyView.
Robert J. Fontana   +6 more
wiley   +1 more source

The biology of the glucocorticoid receptor: new signaling mechanisms in health and disease.

open access: yesJournal of Allergy and Clinical Immunology, 2013
R. Oakley, J. Cidlowski
semanticscholar   +1 more source

Expert Perspective: Hematologic Malignancies and Vasculitis

open access: yes
Arthritis &Rheumatology, EarlyView.
Michelle L. Robinette, Hetty E. Carraway
wiley   +1 more source

Expert Perspective: Diagnosis and Treatment of Castleman Disease

open access: yesArthritis &Rheumatology, EarlyView.
Castleman disease (CD) is a major diagnostic challenge for rheumatologists. Unicentric CD (UCD) involves one enlarged lymph node region, whereas multicentric CD (MCD) involves multiple enlarged lymph node regions. Both UCD and MCD may exhibit a wide range of symptoms that overlap with other immune‐mediated conditions.
Luke Y. C. Chen   +2 more
wiley   +1 more source

Tissue-specific regulation of glucocorticoid receptor mRNA by dexamethasone.

open access: hybrid, 1987
Judith E. Kalinyak   +3 more
openalex   +1 more source

Home - About - Disclaimer - Privacy